Prevention And Treatment Of Prostate Cancer Market: Growth, Demand and Key Players to 2021

1
Prevention And Treatment Of Prostate Cancer
Market size Survey On Product Awareness 2021
2
The global market for prostate cancer products
reached nearly 47.2 billion in 2016 and should
reach nearly 65.1 billion in 2021, with a
compound annual growth rate (CAGR) of
6.6.Report ScopeThe scope of this study is
testing, screening technology and also
therapeutics markets for prostate cancer. The
report also includes the regulatory environment,
current technologies, new technologies, prostate
cancer incidence, market projections and market
share, along with latest trends and new
developments.Get More Information
sample https//www.trendsmarketresearch.com/repor
t/sample/11795Screening for diagnosis, therapy
via drug, surgery or radiation is measured and
broken down by PSA testing, digital rectal exam
(DRE), prostate biopsy, hormone therapy,
chemotherapy, immunotherapy, external beam
radiation therapy (EBRT), prostatectomy and
brachytherapy.Report Includes An overview of
the market for the prevention and treatment of
prostate cancer, with coverage of the mechanisms
of disease development, detection and diagnosis,
and anticancer agents Analyses of global
market trends, with data from 2012, 2016, and
projections of compound annual growth rates
(CAGRs) through 2021
3
Discussion of risk factors, natural history,
epidemiology, and the genetics of prostate
cancer Examinations of prostate-specific
antigen (PSA) screening, including the causes of
PSA changes, PSA thresholds, and controversies
over the screening Coverage of emerging
therapies, including combination therapy,
therapeutic vaccines, inhibitors of kinase
signaling pathways, proteasome inhibitors,
angiogenesis inhibitors, and immunotherapeutic
agents Evaluation of prostate cancer treatment
products by geography, race, and category
Breakdown of the industry structure, including
market shares, trends in price and price
performance, and factors influencing demand
Comprehensive company profiles of major players
in the field.Report SummaryGlobally, prostate
cancer is the second-leading cause of new cancer
cases in men and the sixth-leading cause of
cancer-related death in men. Prostate-related
health issues are on the rise, and the number of
cancer cases is increasing, leading to the need
for improved treatments and diagnostic
technologies. Prostate cancer is the second most
frequently diagnosed cancer in men. In 2013,
there were over 1.4 million incident cases of
prostate cancer and 293,000 deaths. Prostate
cancer caused 4.8 million peopleto live with
disability in 2013, with 57 occurring in
developed countries, and 43 occurring in
developing countries. It is expected that one in
15 men can develop prostate cancer between birth
and age 79 years.
4
In 2013, there were an estimated 2,850,139 men
living with prostate cancer in the U.S. In 2016,
it was estimated that there would be 180,890 new
cases of prostate cancer and an estimated 26,120
people would die of this disease.In prostate
cancer, cells within the prostate, an exocrine
gland mutate into cancer cells. Prostate cancer
(PC) is a disease predominately of the elderly
with 60 of cases diagnosed in men aged 65 or
over. Prostate cancer is slow growing, and
asymptomatic at its earliest stages.Request for
Discount  https//www.trendsmarketresearch.com/re
port/discount/11795The market for prostate
cancer products, including both diagnostic and
treatment modalities, is expected to grow, but
slowly, in the coming years. The driving factors
are an increase in diagnostic tests and the
launch of innovative drugs and technologies.
Elevated serum PSA levels are loosely correlated
with prostate cancer, but many newer diagnostic
procedures are being tested and
implemented.Survival for any type of cancer
depends on its stage at diagnosis, or to the
extent a cancer is present in the body, which
further determines treatment options and has a
strong influence on the length of survival.
5
Digital rectal exams (DREs), prostate biopsies
and prostate-specific antigen (PSA) blood tests
are some of the most common methods used to
diagnose prostate cancer. However, with the use
of DRE, the PSA test, and the incidental
discovery of tumors following resection of the
prostate, the majority of prostate cancer cases
are diagnosed at an early stage (60). As
prostate cancer grows very slowly, the disease
can be left untreated for extended periods of
time with frequent monitoring (watchful waiting
or active surveillance). The challenge is in
separating the patients with aggressive cancers
that need immediate treatment from the patients
with lower-risk cancers that can be monitored at
annual check-ups. At present, many urologists are
looking for new tests. Prostate-specific antigen
(PSA) blood test is not considered a perfect test
for finding prostate cancer early. The new tests
use blood, urine and tissue samples with the goal
to diagnose and predict if it is aggressive
enough and needs treatment or if it can be safely
monitored. Some of these tests have been
validated in retrospective laboratory studies,
only a few have been assessed by the FDA.Report
Analysis  https//www.trendsmarketresearch.com/re
port/analysis/BCC/prevention-and-treatment-of-pros
tate-cancer-market
6
Table Of Contents4 to 5 Points onlyView More
Table of Contents Click Here
7

Brin Singh Address One Vincent
Square, Westminster, London SW1P 2PN United
Kingdom Email brin_at_trendsmarketresearch.com
Web site https//www.trendsmarketresearch.com
Thank You